HSPH1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL20839667	0.73	1/20
SCHEMBL20839977	0.62	1/20
SCHEMBL20852079	0.62	1/20
SCHEMBL20852075	0.60	1/20
SCHEMBL20839645	0.59	1/20
SCHEMBL3903239	0.58	1/20
SCHEMBL20839733	0.58	1/20
SCHEMBL20839781	0.58	1/20
SCHEMBL20839747	0.57	1/20
SCHEMBL20839783	0.57	1/20
SCHEMBL27546577	0.56	1/20
SCHEMBL20839666	0.56	1/20
SCHEMBL20839687	0.55	1/20
SCHEMBL20839937	0.55	1/20
SCHEMBL20852070	0.55	1/20
SCHEMBL20852080	0.55	1/20
SCHEMBL20839658	0.54	1/20
SCHEMBL20839684	0.54	1/20
SCHEMBL20839711	0.54	1/20
SCHEMBL20839752	0.54	1/20

Clinical trials — most relevant to HSPH1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
OGX-427 in Castration Resistant Prostate Cancer Patients	PHASE2	COMPLETED
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)	PHASE1/PHASE2	COMPLETED
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease	PHASE2	COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96	PHASE2	UNKNOWN
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer	PHASE2	COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors	PHASE1	COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors	PHASE1	COMPLETED
HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies	PHASE1	WITHDRAWN
Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma	PHASE1	COMPLETED
Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma	PHASE1	COMPLETED
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas	PHASE1	COMPLETED
Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer	PHASE1	COMPLETED
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors	PHASE1	COMPLETED
Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Exercise on Expression of Heat Shock Protein 70 in Arterial Risk	nan	COMPLETED
Perfusion-Induced Hyperthermia for Metastatic Carcinoma	nan	COMPLETED
LncRNA Nicotinamide Nucleotide Transhydrogenase-Antisense RNA1 NNT-AS1 in CRC	nan	COMPLETED
BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer	nan	UNKNOWN
Possible Diagnostic Protein Markers in Schistosoma Related Bladder Diseases.	nan	NOT_YET_RECRUITING
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)	nan	RECRUITING
Trial of Nonsurgical Treatment of Intermittent Claudication Due to Femoro-popliteal Disease	nan	COMPLETED
Reduced Ventilator-Free Days and Bacterial Colonization of Sub-Glottic Secretions	nan	WITHDRAWN
The Role of HSP90 in Peripheral Vascular Lesions of Diabetic Atherosclerosis	nan	COMPLETED
Acute Passive Heating in Healthy Older Adults	nan	COMPLETED
Chronic Heat Therapy for Improving Vascular Health	nan	COMPLETED
Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia	nan	RECRUITING
Cardioprotective Benefit of Passive Heat Therapy in Higher-Level Spinal Cord Injury: Safety and Proof of Concept	nan	UNKNOWN
Local Heat-Stress as a Mechanism of Hearing Preservation	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a HSPH1 binder may also engage these)

Protein	Name	Similarity
Q0IIM3	—	1.000	Q0IIM3 →
Q5R606	—	1.000	Q5R606 →
Q61699	—	1.000	Q61699 →
Q66HA8	—	1.000	Q66HA8 →
Q60446	—	1.000	Q60446 →
HSPA4L	Heat shock 70 kDa protein 4L	0.998	landscape →
P48722	—	0.993	P48722 →
F4HQD4	—	0.988	F4HQD4 →
Q2TFN9	—	0.984	Q2TFN9 →
Q61316	—	0.982	Q61316 →
HSPA4	Heat shock 70 kDa protein 4	0.981	landscape →
O88600	—	0.981	O88600 →
Q5RDM4	—	0.981	Q5RDM4 →
Q9S7C0	—	0.980	Q9S7C0 →
Q06068	—	0.976	Q06068 →
Q94738	—	0.975	Q94738 →
Q4V7N2	—	0.974	Q4V7N2 →
Q9QW07	—	0.972	Q9QW07 →
Q5ZLV4	—	0.971	Q5ZLV4 →
Q642Q1	—	0.971	Q642Q1 →
PLCB1	1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1	0.970	landscape →
Q9SAB1	—	0.970	Q9SAB1 →
Q90ZA1	—	0.970	Q90ZA1 →
Q07722	—	0.969	Q07722 →
Q7ZY60	—	0.969	Q7ZY60 →
A0A0P0V4R0	—	0.969	A0A0P0V4R0 →
P0C928	—	0.969	P0C928 →
Q93YU6	—	0.969	Q93YU6 →
P10894	—	0.968	P10894 →
O55091	—	0.968	O55091 →